Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire remaining 86.5% stake in Famy Life Sciences Private Limited from the Taparia family for approximately $280 million on November 7, 2022. The consideration will be paid in cash. In a related transaction, Viatris Inc. also entered into a definitive agreement to acquire Oyster Point Pharma, Inc on November 7, 2022. Together, the two acquisitions have an aggregate purchase price of approximately $700-$750 million. Viatris expects to fund with cash on hand. The ophthalmology franchise will function as a separate division within the company and will be led by current Oyster Point Chief Executive Officer, Jeff Nau upon the closing of the transaction. The transaction is subject to customary closing conditions, including receipt of regulatory approval. The transaction is expected to close in the first quarter of 2023. Viatris expects the acquisitions to be accretive to adjusted EPS in 2023 on a standalone basis. Zia Mody, Vaidhyanadhan Iyer and Malaveeka Chakravarthy of AZB & Partners acted as legal advisors to Viatris Inc.

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of remaining 86.5% stake in Famy Life Sciences Private Limited from the Taparia family on January 3, 2023.